GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Teleflex Inc (NYSE:TFX) » Definitions » EBIT

Teleflex (Teleflex) EBIT : $519 Mil (TTM As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Teleflex EBIT?

Teleflex's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $86 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $519 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Teleflex's annualized ROC % for the quarter that ended in Dec. 2023 was 4.31%. Teleflex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 26.65%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Teleflex's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 4.54%.


Teleflex EBIT Historical Data

The historical data trend for Teleflex's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teleflex EBIT Chart

Teleflex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 420.17 424.23 616.44 500.18 519.09

Teleflex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 128.47 115.82 144.72 172.80 85.76

Competitive Comparison of Teleflex's EBIT

For the Medical Instruments & Supplies subindustry, Teleflex's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teleflex's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Teleflex's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Teleflex's EV-to-EBIT falls into.



Teleflex EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $519 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teleflex  (NYSE:TFX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Teleflex's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=539.632 * ( 1 - 48% )/( (6179.478 + 6837)/ 2 )
=280.60864/6508.239
=4.31 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7493.634 - 432.657 - ( 881.499 - max(0, 585.422 - 2097.271+881.499))
=6179.478

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7532.546 - 472.698 - ( 222.848 - max(0, 606.745 - 1407.406+222.848))
=6837

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Teleflex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=343.052/( ( (588.071 + max(717.85, 0)) + (603.434 + max(665.313, 0)) )/ 2 )
=343.052/( ( 1305.921 + 1268.747 )/ 2 )
=343.052/1287.334
=26.65 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(425.194 + 625.075 + 165.503) - (432.657 + 0 + 65.265)
=717.85

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(443.467 + 626.216 + 114.875) - (472.698 + 0 + 46.547)
=665.313

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Teleflex's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=519.094/11439.823
=4.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teleflex EBIT Related Terms

Thank you for viewing the detailed overview of Teleflex's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Teleflex (Teleflex) Business Description

Traded in Other Exchanges
Address
550 East Swedesford Road, Suite 400, Wayne, PA, USA, 19087
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2022 sales), interventional (16%), anesthesia (14%), surgical (14%), interventional urology (12%), original-equipment manufacturing (10%), and all other (10%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.
Executives
Liam Kelly officer: EVP & President, International IDA BUSINESS AND TECHNOLOGY PARK, DUBLIN ROAD, ATHLONE L2 00000
Thomas E Powell officer: Senior Vice President & CFO C/O TOMOTHERAPY INCORPORATED, 1240 DEMING WAY, MADISON WI 53717
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Jaewon Ryu director 950 N. GLEBE ROAD, SUITE 700, ARLINGTON VA 22203
Neena M Patil director JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Andrew A Krakauer director CANTEL MEDICAL CORP., 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Cameron P Hicks officer: Vice President, Global HR 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Klasko Stephen K. M.d. director 155 SOUTH LIMERICK ROAD, LIMERICK PA 19468
Jay White officer: VP & Pres, Global Commercial 3015 CARRINGTON MILL BLVD., MORRISVILLE NC 27560
Daniel V. Logue officer: VP, Gen Counsel & Secretary 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
John Deren officer: VP & Chief Accounting Officer 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
James J Leyden officer: VP, General Counsel, Secretary C/O INFRASOURCE SERVICES, INC, 500 WEST DUTTON MILL ROAD, ASTON PA 19014
James Winters officer: Vice President, Mfg and Supply 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Mario Wijker officer: Vice President, QARA 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Benson Smith director C/O ROCHESTER MEDICAL INC, ONE ROCHESTER MEDICAL DDRIVE, STEWARTVILLE MN 55976